The Latest Treatments in Cancer Care

New York Cancer & Blood Specialists is at the forefront of making cancer care more personalized by detecting genetic abnormalities (mutations) specific to each patient’s tumor. With advancements in technology, we can now identify these targets from biopsy specimens and blood samples, offering a less invasive approach. In addition, we can administer drugs that effectively attack tumor cells by targeting these specific mutations while minimizing harm to healthy cells, unlike traditional chemotherapy.

Our patients have access to national networks, ensuring that even patients with rare mutations have opportunities to participate in innovative clinical trials within their local community. We also offer a range of treatments that stimulate the patient's immune system to specifically target and fight against cancer, either as standalone therapies or in combination with chemotherapy.

One of the groundbreaking approaches we provide is "hybrid" therapies, where chemotherapy drugs are fused with monoclonal antibodies. These antibodies act as guided missiles, specifically attaching to cancer cells and delivering their toxic chemotherapy payloads directly to the cancer, sparing normal tissues. This targeted approach concentrates the treatment's effect on the cancer itself, minimizing collateral damage.